Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

Abstract Number: 0906 • ACR Convergence 2022
Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients
Natalia Carbonell-Bobadilla¹, Carina Soto-Fajardo², Luis M Amezcua-Guerra³, Ana Beatriz Batres Marroquin⁴, Ana Cristina Medina⁵, Tania Vargas³, Adrián Hernández-Diazcouder³, Valentín Jiménez-Rojas³, Carlos Pineda⁵ and Luis H Silveira⁶, ¹National Institute of Cardiology Ignacio Chávez, Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ⁴Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, Mexico, ⁵Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ⁶Instituto Nacional de Cardiología, Ciudad de México, Mexico
Background/Purpose: Seronegative rheumatoid arthritis (SNRA) tends to be less severe in its presentation and evolution than seropositive rheumatoid arthritis(SPRA), but controversy exists because there have…
Abstract Number: 0914 • ACR Convergence 2022
The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials
Kaoru Takase-Minegishi¹, Stephan Böhringer², Jackie Nam³, Yuko Kaneko⁴, Frank Behrens⁵, Saedis Saevarsdottir⁶, Jacqueline Detert⁷, Marjatta Leirisalo-Repo⁸, Désirée van der Heijde⁹, Robert Landewé¹⁰, Sofia Ramiro¹¹ and Diane van der Woude¹², ¹Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ²Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, United Kingdom, ⁴Keio University School of Medicine, Tokyo, Japan, ⁵CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, ⁶Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden and Faculty of Medicine, University of Iceland, Stockholm, Sweden, ⁷Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁸Department of Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ¹⁰Amsterdam University Medical Center, Meerssen, Netherlands, ¹¹Leiden University Medical Center, Leiden, Netherlands, ¹²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The impact of autoantibodies on the efficacy of bDMARDs in patients with rheumatoid arthritis (RA) is not yet clear. Despite the fact that this…
Abstract Number: 1203 • ACR Convergence 2022
The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical Interstitial Lung Disease in Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis
Jenna Lanz¹, Jan Hughes-Austin², Anna Podolanczuk³, John Kim⁴, John Austin⁵, William Robinson⁶, Ganesh Raghu⁷, Eric Hoffman⁸, John Newell Jr⁸, Jubal Watts Jr⁹, P. Hrudaya Nath⁹, Sushilkumar Sonavane¹⁰, R. Graham Barr⁵ and Elana Bernstein¹, ¹Columbia University, New York, NY, ²University of California, San Diego, San Diego, CA, ³Weill Cornell Medical College, New York, NY, ⁴University of Virginia School of Medicine, Charlottesville, VA, ⁵Columbia University Medical Center, New York, NY, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷University of Washington, Seattle, WA, ⁸University of Iowa, Iowa City, IA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Mayo Clinic, Rochester, MN
Background/Purpose: We previously demonstrated a significant association between serum anti-CCP levels and prevalence of interstitial lung abnormalities (ILA) in community-dwelling adults. A greater number of…
Abstract Number: 1406 • ACR Convergence 2022
Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis
Benjamin Hur¹, Kevin Cunningham², John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²University of Minnesota, Rochester, MN
Background/Purpose: ACPA detection assays are often used for RA diagnosis due to their high specificity ( >90%). However, current ACPA assays (e.g., anti-CCP2 ELISA) have…
Abstract Number: 1417 • ACR Convergence 2022
Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice
Gordon Lam¹, Hanke Zheng², Emily Bland³, Vardhaman Patel⁴, Laetitia N’Dri⁵, Parisa Asgarisabet³, Keith Wittstock⁴, Cherrishe Brown-Bickerstaff³, Mark Chaballa², Bruce Feinberg³, Vadim Khaychuk⁶ and Andrew J Klink³, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Bristol Myers Squibb, Princeton, NJ, ³Cardinal Health, Dublin, OH, ⁴Bristol Myers Squibb, Lawrence Township, NJ, ⁵Bristol Myers Squibb, Princeton, ⁶Bristol Myers Squibb, Pennington, MA
Background/Purpose: Early intensive treatment (tx) is an accepted paradigm in the tx of patients (pts) with RA with poor prognostic factors (eg, RF/ACPA seropositivity); however,…
Abstract Number: 1606 • ACR Convergence 2022
An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis
nozima Aripova¹, George Reed², Bryant England¹, William Robinson³, Dimitrios Pappas⁴, Joel Kremer⁵, Geoffrey Thiele¹ and Ted Mikuls⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²The Corrona Research Foundation and University of Massachusetts, Albany, NY, ³Stanford University School of Medicine, Palo Alto, CA, ⁴CorEvitas, LLC, Waltham, MA, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) treatments have advanced with the availability of biologic therapies. Despite these advances, 30-40% of patients receiving a biologic do not adequately…
Abstract Number: 1685 • ACR Convergence 2022
The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis
Alexandra Taylor¹, Michael Duryee², Carlos Hunter², nozima Aripova², Ted Mikuls³ and Geoffrey Thiele², ¹Creighton University School of Medicine, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Antibodies to malondialdehyde-acetaldehyde protein adducts (MAA) are increased in both the serum and synovial joint fluid from patients with Rheumatoid Arthritis (RA). These antibodies…
Abstract Number: 1965 • ACR Convergence 2022
Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis
Hsin-Yi Peng¹, Ting-Yin Xue¹, Fei-Hung Hsieh¹, Yi-Ko Chen¹, Mei-Chin Yin², Che-Yi Chao², Shu-Yao Tsai², Chung-Ping Lin³, Po-Hao Huang³, Chien-Chung Huang³, Jiunn-Horng Chen³, Chung-Ming Huang³, Der-Yuan Chen⁴, Joung-Liang Lan⁵ and Gregory Tsay³, ¹China Medical University, Taichung, Taiwan, ²Asia University, Taichung, Taiwan, ³China Medical University Hospital, Taichung, Taiwan, ⁴China Medical University Hospital Rheumatology and Immunology Center, Taichung, Taiwan, ⁵China Medoical University Hospital, Taichung, Taiwan
Background/Purpose: The presence of rheumatoid factor (RF) or anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the 2010 the ACR/EULAR classification criteria of rheumatoid arthritis…
Abstract Number: 0038 • ACR Convergence 2021
Arthritis Progression in at Risk Individuals Is Associated with ACPAs Not AMPAs
Alexandra Circiumaru¹, Yogan Kisten², Monika Hansson², Heidi Wähämaa³, Meng Sun³, Vijay Joshua³, Hamed Rezaei⁴, Erik Af Klint⁴, Aleksandra Antovic¹, Anca Catrina³ and Aase Haj Hensvold⁵, ¹Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet and Karolinska university Hospital, Stockholm, Sweden, ⁴Division for Rheumatology, Karolinska Institutet; Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Individuals with anti citrullinated protein antibodies (ACPA) and musculoskeletal complaints are at high risk for developing rheumatoid arthritis (RA) and often seek medical attention…
Abstract Number: 1654 • ACR Convergence 2021
Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia
Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
Abstract Number: 0039 • ACR Convergence 2021
Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?
Veerle Derksen, Cornelia F. Allaart, Annette H.M van der Helm-van Mil, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Mucosal surfaces may be involved in the pathophysiology of rheumatoid arthritis (RA) (1). IgA is the most abundant class of immunoglobulin at mucosal sites…
Abstract Number: 0042 • ACR Convergence 2021
High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis
Michael Richter¹, Hari Krishnamurthy², Sylvia Posso³, Jeffrey Carlin⁴ and Jane Buckner³, ¹University of Washington, Mercer Island, WA, ²Vibrant Sciences, San Carlos, CA, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Virginia Mason Medical Center, Seattle, WA
Background/Purpose: Antibodies to citrullinated and other modified proteins play a critical role in the pathogenesis of rheumatoid arthritis (RA). The prevalence and degree of multi-site…
Abstract Number: 0228 • ACR Convergence 2021
Optimizing Social Media as a Recruitment Tool for Hard-to-Reach Populations in Rheumatology Clinical Research
Vladislav Tsaltskan¹, Katherine Nguyen¹, Christina Eaglin¹, Kevin Deane², V. Michael Holers³ and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²University of Colorado Denver, Denver, CO, ³University of Colorado, Denver, CO
Background/Purpose: Standard methods of recruitment for clinical research, such as traditional media advertisements, can be inefficient and expensive, especially for underserved communities and asymptomatic individuals.…
Abstract Number: 0269 • ACR Convergence 2021
Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Jeremy Sokolove³, William Robinson⁴, Joshua Baker⁵, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Stanford University School of Medicine, Berwyn, PA, ⁴Stanford University, Stanford, CA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
Abstract Number: 0288 • ACR Convergence 2021
Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies
Gregory McDermott¹, Ritu Gill², Staci Gagne³, Suzanne Byrne³, Weixing Huang³, Lauren Prisco⁴, Alessandra Zaccardelli³, Lily Martin³, Nancy Shadick⁵, Paul Dellaripa³, Tracy Doyle⁶ and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Pound Ridge, MA, ⁵Brigham & Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Bronchiectasis is a known extra-articular manifestation of rheumatoid arthritis (RA) characterized by bronchial damage and excessive mucus production that predispose patients to risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].